Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 217 of the 224 references it cites were found in a registry or an index.

Antisense technology: an overview and prospectus

Crooke, Stanley T., Baker, Brenda F., Crooke, Rosanne M., Liang, Xue-hai · 2021 · Nature Reviews Drug Discovery

Abstract

Antisense technology is now beginning to deliver on its promise to treat diseases by targeting RNA. Nine single-stranded antisense oligonucleotide (ASO) drugs representing four chemical classes, two mechanisms of action and four routes of administration have been approved for commercial use, including the first RNA-targeted drug to be a major commercial success, nusinersen. Although all the approved drugs are for use in patients with rare diseases, many of the ASOs in late- and middle-stage clinical development are intended to treat patients with very common diseases. ASOs in development are showing substantial improvements in potency and performance based on advances in medicinal chemistry, understanding of molecular mechanisms and targeted delivery. Moreover, the ASOs in development include additional mechanisms of action and routes of administration such as aerosol and oral formulations. Here, we describe the key technological advances that have enabled this progress and discuss recent clinical trials that illustrate the impact of these advances on the performance of ASOs in a wide range of therapeutic applications. We also consider strategic issues such as target selection and provide perspectives on the future of the field.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41573-021-00162-z

Cites

217 of 217 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 224 references

Research works printed but not linked: 5

  1. Yu, R. Z. et al. Investigation of oral delivery of GalNac3 conjugated antisense oligonucleotides in rats. in DIA/FDA Oligonucleotide-Based Therapeutics Conference (FDA and DIA, 2019). This study reports that a PS MOE GalNAc-conjugated ASO can be delivered orally.
  2. Panzara, M. Stereopure nucleic acid therapies in development for the treatment of genetic neurological diseases. Neurotherapeutics 14, 821–822 (2017).
  3. Yuen, M. F. et al. Phase 2a, randomized, double-blind, placebocontrolled study of an antisense inhibitor (ISIS 505358) in treatment-naïve chronic hepatitis B (CHB) patients: safety and antiviral efficacy. Hepatology 70, 437A–438A (2019).
  4. Bell, D. et al. Safety, tolerability, and target engagement demonstrated with inhaled αENaC antisense oligonucleotide (ION-827359) in a phase 1 healthy volunteer study. Presented at the North American Cystic Fibrosis Conference (2020).
  5. Bhanot, S. et al. ISIS-GCCRRX, a novel glucocorticoid (GC) receptor antisense drug reduces cholesterol and triglycerides and attenuates dexamethasone induced hepatic insulin resistance without systemic GC antagonism in normal subjects. Diabetologia 56, S282 (2013).

Cited by

See all 837

Metadata

Authors
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H.
Affiliations
Ionis Pharmaceuticals (United States) (US)
Corresponding author
Crooke, Stanley T.
Venue
Nature Reviews Drug Discovery
Published
2021-03-24
Volume
20
Issue
6
Pages
427-453
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W3137153690
Cited by
775
References
224
Citations by year
2026: 163 · 2025: 162 · 2024: 161 · 2023: 125 · 2022: 120 · 2021: 43
FWCI
11.78
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
Keywords
antisense oligonucleotides, RNA-targeted drugs, nusinersen, rare diseases, antisense drug development, drug delivery, aerosol formulation, oral dosage forms, target selection, clinical trials
MeSH terms
Animals, Biological Therapy, Chemistry, Pharmaceutical, Disease, Humans, Oligonucleotides, Antisense, Drug Delivery Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antisense technology: an overview and prospectus. https://app.cochat.ai/papers/10.1038/s41573-021-00162-z
The paper
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021). Antisense technology: an overview and prospectus. Nature Reviews Drug Discovery. https://doi.org/10.1038/s41573-021-00162-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.